Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of Viz Agent ...

Enhanced Phase 2 dose-optimization study designed to accelerate development and support a streamlined Phase 3 programMELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex ...

- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy ...

Early 2026 has brought a series of consequential regulatory moves from the FDA, each reflecting a common thread: the agency ...

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...

Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...

Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...

Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...

Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...